IL18 and amyotrophic lateral sclerosis: However, clinical studies with anakinra in ALS patients have not shown a significant reduction in disease progression (Maier et al, 2015), suggesting that inflammasome activation does not play a major role in ALS, or that the pathology is driven by IL‐18 or by DAMPs via pyroptosis.